S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:INAB

IN8bio (INAB) Stock Price, News & Analysis

$1.18
-0.03 (-2.48%)
(As of 03/28/2024 ET)
Today's Range
$1.18
$1.27
50-Day Range
$0.95
$1.44
52-Week Range
$0.65
$3.95
Volume
93,516 shs
Average Volume
174,333 shs
Market Capitalization
$37.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.83

IN8bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
733.3% Upside
$9.83 Price Target
Short Interest
Healthy
0.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of IN8bio in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.70) to ($0.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.91 out of 5 stars

Medical Sector

542nd out of 938 stocks

Biological Products, Except Diagnostic Industry

88th out of 151 stocks

INAB stock logo

About IN8bio Stock (NASDAQ:INAB)

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

INAB Stock Price History

INAB Stock News Headlines

4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
IN8bio (NASDAQ:INAB) Receives Buy Rating from HC Wainwright
IN8bio's (INAB) Buy Rating Reiterated at HC Wainwright
IN8bio (NASDAQ:INAB) Stock Rating Reaffirmed by HC Wainwright
INAB Stock Earnings: IN8bio Misses EPS for Q4 2023
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
IN8bio to Present at Upcoming Investor Conferences
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
See More Headlines
Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:INAB
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.83
High Stock Price Target
$14.00
Low Stock Price Target
$7.50
Potential Upside/Downside
+733.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-30,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.78 per share

Miscellaneous

Free Float
21,434,000
Market Cap
$37.75 million
Optionable
Not Optionable
Beta
-0.03
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Tai-Wei Ho (Age 47)
    Co-Founder, President, CEO & Director
    Comp: $837k
  • Dr. Kate Rochlin Ph.D. (Age 43)
    Chief Operating Officer
    Comp: $565.4k
  • Dr. Trishna Goswami M.D. (Age 46)
    Chief Medical Officer
    Comp: $638.51k
  • Dr. Lawrence S. Lamb Ph.D. (Age 70)
    Executive VP, Co-Founder & Chief Scientific Officer
    Comp: $482.47k
  • Mr. Patrick McCall CPA (Age 41)
    CFO & Secretary
    Comp: $519.35k
  • Mr. Michael McNamara
    Vice President of Accounting

INAB Stock Analysis - Frequently Asked Questions

Should I buy or sell IN8bio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INAB shares.
View INAB analyst ratings
or view top-rated stocks.

What is IN8bio's stock price target for 2024?

3 analysts have issued 12-month target prices for IN8bio's stock. Their INAB share price targets range from $7.50 to $14.00. On average, they anticipate the company's share price to reach $9.83 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price.
View analysts price targets for INAB
or view top-rated stocks among Wall Street analysts.

How have INAB shares performed in 2024?

IN8bio's stock was trading at $1.38 on January 1st, 2024. Since then, INAB stock has decreased by 14.5% and is now trading at $1.18.
View the best growth stocks for 2024 here
.

Are investors shorting IN8bio?

IN8bio saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 84,800 shares, an increase of 296.3% from the February 29th total of 21,400 shares. Based on an average daily trading volume, of 184,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.3% of the company's stock are short sold.
View IN8bio's Short Interest
.

When is IN8bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our INAB earnings forecast
.

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05.

When did IN8bio IPO?

IN8bio (INAB) raised $44 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 4,000,000 shares at $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO.

Who are IN8bio's major shareholders?

IN8bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (12.81%), Vanguard Group Inc. (1.30%), Vanguard Group Inc. (1.30%), Voss Capital LLC (1.07%), Sigma Planning Corp (0.41%) and Texas Capital Bank Wealth Management Services Inc (0.25%). Insiders that own company stock include Emily Fairbairn, Jeremy R Graff, Kate Rochlin, Lawrence Lamb, Patrick Mccall, Trishna Goswami and William Tai-Wei Ho.
View institutional ownership trends
.

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INAB) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners